TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01000662

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Daily Radiation Therapy
Description: 15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Radiation Therapy
Description: 15 weekly radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
Study: NCT02289183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic distal gastrectomy
Description: Totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy-assisted distal gastrectomy
Description: Laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis
Study: NCT00753870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCRE inhalation
Description: 20,000 EU CCRE given as a one-time challenge
Study: NCT02230631

Intervention type: OTHER
Intervention: No treatment given
Description: Two different questionnaires will be applied to patients during a regular clinical visit.

Intervention type: OTHER
Intervention: No treatment given
Description: Two different questionnaires will be applied to patients during a regular clinical visit.
Study: NCT01280136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: It's Your Game Tech
Description: An interactive web-based intervention for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game...Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
Study: NCT00639249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA4503 Low
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA4503 High
Description: Oral administration
Study: NCT04270474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deprescribing of target anticholinergics
Description: The active intervention group (ACT) will receive a pharmacist-based deprescribing intervention focused only on targeted anticholinergic medications. The intervention pharmacist will serve as the central source of communication between participants, providers, and (as needed) dispensing pharmacy to coordinate the deprescribing process. The study pharmacists will navigate a shared-decision model between the physicians and participant in order to personalize the selection of appropriate alternatives and switch/titration schedules. Importantly, the pharmacist will supervise the titration and deprescribing plan and communicate with both participants and physicians throughout the study.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: Those in the usual care group will not have access to the study intervention, but will receive a one-time information packet through the mail reviewing risks of polypharmacy, but no information specific to anticholinergic medications. They will receive clinical care as usually provided by their primary care or specialty care physicians.
Study: NCT02646982

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched placebo will be given once daily for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP\>100 mm Hg, DBP\>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.
Study: NCT01671852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate nasal spray
Description: Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.~For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03891940

Intervention type: PROCEDURE
Intervention: patients recieving anterior cervical spine surgery
Description: Anterior cervical discectomy with fusion, or ACDF, is a surgery designed to relieve spinal cord or nerve root pressure in the neck by removing all or part of a damaged disc
Study: NCT01049841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine + temsirolimus
Description: The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
Study: NCT01594853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
Study: NCT02027103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
Study: NCT01248351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous stored platelets
Description: Administration of autologous stored platelets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: administration of autologous stored platelets
Description: administration of autologous stored platelets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous stored platelets
Description: transfusion of autologous stored platelets
Study: NCT03655613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APL-501
Description: Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101
Description: Oral specific c-Met inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101
Description: Oral specific c-Met inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Fully human IgG4 monoclonal antibody against PD-1
Study: NCT04006964

Intervention type: DEVICE
Intervention: Resmon PRO FULL v2
Description: Measurement of lung impedance by the Forced Oscillation Technique

Intervention type: DEVICE
Intervention: Resmon PRO FULL v2
Description: Measurement of lung impedance by the Forced Oscillation Technique
Study: NCT04989920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group: CIMT group (Constraint-Induced Movement Therapy)
Description: 2 weeks of intensive therapy delivered 5d/week for 6 hrs/day
Study: NCT01854619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photodisinfection (antimicrobial photodynamic therapy, aPDT)
Description: A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photodisinfection (antimicrobial photodynamic therapy, aPDT)
Description: A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline irrigation
Description: The active comparator arm will receive saline irrigation via syringe that is administered using a sinus irrigation catheter under endoscopic control.
Study: NCT01676714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Study: NCT01489839

Intervention type: OTHER
Intervention: Periodontal therapy
Description: All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.

Intervention type: OTHER
Intervention: Periodontal therapy
Description: All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.
Study: NCT03559855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real Essentials
Description: The REAL Essentials curriculum is a healthy relationship education program for youth developed by the Center for Relationship Education.
Study: NCT04034160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vegetarian burger
Description: A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 1 will be given vegetarian burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: beef burger
Description: A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 2 will be given beef burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched.
Study: NCT04788355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group (standard hospital treatment)
Description: Medications defined by the hospital involved in the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control group (standard hospital treatment)
Description: Medications defined by the hospital involved in the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control group (standard hospital treatment)
Description: Medications defined by the hospital involved in the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control group (standard hospital treatment)
Description: Medications defined by the hospital involved in the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group Hydroxychloroquine
Description: Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days. In addition, patients in this group will receive standard medication for COVID-19 which is part of the hospital protocol involved in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group Hydroxychloroquine and apixaban
Description: Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days + apixaban orally 2.5 mg every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group Apixaban
Description: Patients in this group will receive apixaban 2.5 mg orally every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
Study: NCT00872105

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-operative Treatment
Description: Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative Treatment
Description: The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:~Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)
Study: NCT02698735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
Study: NCT04485520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CARICA PAPAYA MOUTHWASH
Description: Each application was 10 ml. applied for 1 minute, once a day for 8 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHLORHEXIDINE MOUTHWASH
Description: Each application was 10 ml. applied for 1 minute, once a day for 8 days
Study: NCT01094769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose capsule taken once daily
Study: NCT00887237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT with triple site ventricular stimulation
Description: CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cardiac resynchronization
Description: Conventional cardiac resynchronization
Study: NCT01294670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat and Etoposide
Description: Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
Study: NCT01871974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: oral
Study: NCT03490305

Intervention type: PROCEDURE
Intervention: Exploratory laparotomy
Description: Findings and procedures done at exploratory laparotomy

Intervention type: PROCEDURE
Intervention: Exploratory laparotomy
Description: Findings and procedures done at exploratory laparotomy
Study: NCT00661531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrace
Description: Estrace 10 mg three times daily will be administered for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
Study: NCT03405259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Super Seal® Desensitizer
Description: Single dose professional application.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acclean® Fluoride Varnish
Description: Single dose professional application.
Study: NCT01146873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: Children are assigned to begin a EFV-based antiretroviral based regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Description: Children are assigned to stay on their current LPV/r-based antiretroviral regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine (D4T)
Description: Children are assigned to stay on their current antiretroviral regimen which includes D4T.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Description: Children stop taking D4T and switch to ABC.
Study: NCT01068028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: Ascending multiple doses to sequential panels

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ORM-12741
Study: NCT02414386

Intervention type: OTHER
Intervention: biospecimen retention
Description: biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels

Intervention type: OTHER
Intervention: biospecimen retention
Description: biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels
Study: NCT00945776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly phone calls
Description: Calling weekly to answer questions regarding CPAP usage.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Frequently asked questions
Description: Answers to frequently asked questions in pre-printed form.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
Study: NCT00404014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL-208
Description: 1 dose of 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose of placebo
Study: NCT01650636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Partner Videotelephone-delivered Health Information (PP-T-HI)
Description: Ten (10) 90-min sessions of Health Information delivered via videophones

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Partner Videotelephone-delivered Cognitive Behavioral Stress Management intervention (PP-T-CBSM)
Description: Ten (10) 90-min sessions of T-PP-CBSM